Loading
A phase 3 trial of Apalutamide and Bicalutamide in prostate cancer, run by Aragon Pharmaceuticals, Inc., active and no longer recruiting.
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS is a phase 3 interventional study registered as NCT02531516 by Aragon Pharmaceuticals, Inc., with 1503 participants enrolled, started 2015-11-19 and due to reach its primary completion in 2027-03-01. Interventions recorded: Apalutamide, Bicalutamide, Bicalutamide Placebo, Apalutamide Placebo, GnRH (agonist) and 74-80 Grays (units of radiation).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Apalutamide, Localised prostate cancer, high and very high risk, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson and the tag pipeline.
Shares Apalutamide, Localised prostate cancer, high and very high risk, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson and the tag pipeline.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson and the tag pipeline.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Bicalutamide, Localised prostate cancer, high and very high risk, Prostate cancer and the tag pipeline.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Johnson & Johnson, Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/